Collectively, our results emphasize the role of DLL4 stimulation in NOTCH1-mutated CLL and confirm the specific therapeutic targeting of Notch1 as a promising approach for this group of poor prognosis CLL patients. Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.